March 2027 biotech catalysts
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-03-01 in 4mo
ESTIMATED |
READOUT
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for
Phase 2 · Babesiosis |
SXTP 60 DEGREES PHARMACEUTICALS, | Tafenoquine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-29
Sponsor-projected date — can change
|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-ex
Phase 2 · HIV-1-infection |
GILD GILEAD SCIENCES, INC. | Oral Lenacapavir, Subcutaneous Lenacapav |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-29
Sponsor-projected date — can change
|
| 2027-03-01 in 4mo
ESTIMATED |
READOUT
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in
Phase 2/3 · Diabetic Macular Edema (DME) |
EyeBiotech Ltd. | Remigromig, Ranibizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-29
Sponsor-projected date — can change
|
| 2027-03-01 in 4mo
ESTIMATED |
READOUT
A Research Study to Look at How Well CagriSema Helps People Living With Obesity
Phase 3 · Obesity |
NVO NOVO NORDISK A S | CagriSema (Cagrilintide B and Semaglutid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-29
Sponsor-projected date — can change
|